Evidence map›Paper›PMID 26391398›Full record

ArticleThe Journal of biological chemistry2015

Ac2PIM-responsive miR-150 and miR-143 target receptor-interacting protein kinase 2 and transforming growth factor beta-activated kinase 1 to suppress NOD2-induced immunomodulators.

Praveen Prakhar, Sahana Holla, Devram Sampat Ghorpade, Martine Gilleron, Germain Puzo, Vibha Udupa, Kithiganahalli Narayanaswamy Balaji

RetractedErratum issuedOpen access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Praveen PrakharFrom the Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore 560012, Karnataka, India and.
Sahana HollaFrom the Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore 560012, Karnataka, India and.
Devram Sampat GhorpadeFrom the Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore 560012, Karnataka, India and.
Martine GilleronInstitut de Pharmacologie et de Biologie Structurale (IPBS), CNRS and Université de Toulouse, 31077 Toulouse, France.
Germain PuzoInstitut de Pharmacologie et de Biologie Structurale (IPBS), CNRS and Université de Toulouse, 31077 Toulouse, France.
Vibha UdupaFrom the Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore 560012, Karnataka, India and.
Kithiganahalli Narayanaswamy BalajiFrom the Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore 560012, Karnataka, India and balaji@mcbl.iisc.ernet.in.
Indian Institute of Science Bangalore · INInstitut de Pharmacologie et de Biologie Structurale · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Specific and coordinated regulation of innate immune receptor-driven signaling networks often determines the net outcome of the immune responses. Here, we investigated the cross-regulation of toll-like receptor (TLR)2 and nucleotide-binding oligomerization domain (NOD)2 pathways mediated by Ac2PIM, a tetra-acylated form of mycobacterial cell wall component and muramyl dipeptide (MDP), a peptidoglycan derivative respectively. While Ac2PIM treatment of macrophages compromised their ability to induce NOD2-dependent immunomodulators like cyclooxygenase (COX)-2, suppressor of cytokine signaling (SOCS)-3, and matrix metalloproteinase (MMP)-9, no change in the NOD2-responsive NO, TNF-α, VEGF-A, and IL-12 levels was observed. Further, genome-wide microRNA expression profiling identified Ac2PIM-responsive miR-150 and miR-143 to target NOD2 signaling adaptors, RIP2 and TAK1, respectively. Interestingly, Ac2PIM was found to activate the SRC-FAK-PYK2-CREB cascade via TLR2 to recruit CBP/P300 at the promoters of miR-150 and miR-143 and epigenetically induce their expression. Loss-of-function studies utilizing specific miRNA inhibitors establish that Ac2PIM, via the miRNAs, abrogate NOD2-induced PI3K-PKCδ-MAPK pathway to suppress β-catenin-mediated expression of COX-2, SOCS-3, and MMP-9. Our investigation has thus underscored the negative regulatory role of Ac2PIM-TLR2 signaling on NOD2 pathway which could broaden our understanding on vaccine potential or adjuvant utilities of Ac2PIM and/or MDP.

Indexed as

Acetylmuramyl-Alanyl-IsoglutamineAnimalsCell LineCyclooxygenase 2Epigenesis, GeneticImmunity, InnateImmunologic FactorsMacrophagesMAP Kinase Kinase Kinase 7MAP Kinase Kinase KinasesMatrix Metalloproteinase 9MiceMice, Inbred C57BLMice, KnockoutMicroRNAsMitogen-Activated Protein KinasesAcetylmuramyl-Alanyl-IsoglutamineCyclooxygenase 2Immunologic FactorsMAP Kinase Kinase Kinase 7MAP Kinase Kinase KinasesMatrix Metalloproteinase 9MicroRNAsMIRN143 microRNA, mouseMirn150 microRNA, mouseMitogen-Activated Protein KinasesMmp9 protein, mouseNitric OxideNod2 protein, mouseNod2 Signaling Adaptor ProteinPhosphatidylinositol 3-KinasesPolysaccharides, BacterialPtgs2 protein, mouseReceptor-Interacting Protein Serine-Threonine Kinase 2Receptor-Interacting Protein Serine-Threonine KinasesRipk2 protein, mouseSocs3 protein, mouseSuppressor of Cytokine Signaling 3 ProteinSuppressor of Cytokine Signaling ProteinsTlr2 protein, mouseToll-Like Receptor 2innate immunitymacrophagemicroRNA (miRNA)Nod-like receptor (NLR)signal transductiontoll-like receptor (TLR)

Identifiers

PMID26391398
PMCPMC4646315
OpenAlexW2201387342

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.